JCM
FBRX icon

Jacobi Capital Management’s Forte Biosciences FBRX Stock Holding History

Jacobi Capital Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-17
Closed -$1K – 705
2021
Q3 		$1K Hold
17
– – ﹤0.01% 1380
2021
Q2 		$14K Hold
17
– – ﹤0.01% 938
2021
Q1 		$15K Hold
17
– – ﹤0.01% 850
2020
Q4 		$15K Buy
+17
New +$16K ﹤0.01% 776

Other funds holding FBRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jacobi Capital Management's FBRX Position: Q4 2021 in Review

Jacobi Capital Management sold out of Forte Biosciences (FBRX) in Q4 2021, closing a stake of 17 shares — an estimated $1K sold.

Jacobi Capital Management first reported a position in FBRX in Q4 2020 and held it in 4 quarters. The position peaked at $15K in Q1 2021. 52 funds tracked by Wall St. Rank hold FBRX as of Q4 2021.

  • Jacobi Capital Management reported no remaining Forte Biosciences position as of Q4 2021 after selling out during the quarter.
  • Jacobi Capital Management sold 17 Forte Biosciences shares in Q4 2021, an estimated $1K.
  • Jacobi Capital Management first reported a position in Forte Biosciences in Q4 2020 and held it in 4 quarters.
  • Jacobi Capital Management's Forte Biosciences position peaked at $15K in Q1 2021.
  • 52 funds tracked by Wall St. Rank held Forte Biosciences as of Q4 2021.

Based on Jacobi Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.